Sponsor content
60 result(s) found, displaying 11 to 20
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for TEPMETKO tepotinib 225 mg (as hydrochloride monohydrate) tablet blister pack.
-
Designation or determinationOrphan drug
-
Australian Public Assessment Report (AusPAR)Tepmetko (tepotinib) for treatment of non-small cell lung cancer with MET exon 14 skipping alterations.
-
Prescription medicine decision summaryTGA decision: Tepmetko (tepotinib) is approved to treat locally advanced or metastatic non-small cell lung cancer (NSCLC).
-
Prescription medicine registrationActive ingredients: tepotinib hydrochloride monohydrate.
-
Prescription medicine registrationActive ingredients: tepotinib hydrochloride monohydrate.
-
Designation or determinationProvisional approval
-
Designation or determinationOrphan drug
-
Prescription medicine registrationActive ingredients: avelumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PERGOVERIS follitropin alfa (rch) /lutropin alfa (rch) 900 IU/450 IU in 1.44 mL solution for injection cartridge pre-assembled in a pen.